Millions of people worldwide suffer from Hepatitis C. Viekira Pak and Harvoni are both prescription drugs used to treat Hepatitis C.
Harvoni is a combination of two drugs: ledipasvir and sofosbuvir. Viekira Pak contains a combination of antiviral medications, ritonavir, ombitasvir, and paritaprevir, packaged with dasabuvir tablets. Both Hepatitis C medications are a once-daily package that has shown incredible results in hepatitis patients. Many times the real world results of drugs differ largely from the clinical trials. So, how do Harvoni and Viekira Pak fare in comparison?
According to Gail Bridges, PharmD, from Accredo Health, the data indicates that credos patients are able to achieve results that are similar to the results that have been found during clinical trials. Patients undergoing treatment using any one of the drugs were able to achieve an average sustained viral response rate. While comparing the real world and clinical trial results Bridges found the clinical surrogate marker for cure of 96% average, which was on par with the mid 90s percentage found under clinical trials.
These uniform results depend on a number of factors. The first being that the two drugs are very effective agents. Dr. Bridges was also quick to point out that the medical community has become savvy when it comes to working with direct acting antiviral by following robust guidelines that help clinicians make smart choices.